Brief Report: Safety and Antitumor Activity of Durvalumab Plus Tremelimumab in PD-(L)1-Monotherapy Pretreated, Advanced Non-Small Cell Lung Cancer: Results From a Phase 1b Clinical Trial.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer（2023）
摘要
Durvalumab plus tremelimumab had a manageable safety profile, but the combination did not show efficacy following PD-(L)1 treatment failure.
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要